Axsome Capital Expenditures vs Net Income Analysis

AXSM Stock

USD 86.95 3.78 4.17%

Axsome Therapeutics financial indicator trend analysis is way more than just evaluating Axsome Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axsome Therapeutics is a good investment. Please check the relationship between Axsome Therapeutics Capital Expenditures and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Capital Expenditures vs Net Income

Capital Expenditures vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axsome Therapeutics Capital Expenditures account and Net Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Axsome Therapeutics' Capital Expenditures and Net Income is -0.94. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Net Income in the same time period over historical financial statements of Axsome Therapeutics, assuming nothing else is changed. The correlation between historical values of Axsome Therapeutics' Capital Expenditures and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Axsome Therapeutics are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Capital Expenditures i.e., Axsome Therapeutics' Capital Expenditures and Net Income go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Axsome Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Axsome Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Axsome Therapeutics financial statement analysis. It represents the amount of money remaining after all of Axsome Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 24th of December 2024, Tax Provision is likely to grow to about 1 M, while Sales General And Administrative To Revenue is likely to drop 0.78.

	2021	2022	2023	2024 (projected)
Interest Expense	5.7M	7.3M	6.5M	6.8M
Depreciation And Amortization	1.2M	5.6M	6.8M	7.2M

Interest Expense Depreciation And Amortization

Axsome Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Non Current Liabilities Total
Total Assets		0.83	0.86	0.86	0.71	-0.8	-0.74	0.81	0.87	0.87	0.42	0.48	0.87	0.75	0.85	0.89	-0.06	0.51	0.43	0.41	0.59	0.84	0.79	0.55	0.82	0.84
Short Long Term Debt Total	0.83		0.98	0.98	0.5	-0.77	-0.97	0.95	0.93	0.93	0.59	0.68	0.94	0.98	1.0	0.96	-0.22	0.67	0.54	0.23	0.78	0.92	0.86	0.02	1.0	1.0
Other Current Liab	0.86	0.98		0.99	0.62	-0.72	-0.94	0.95	0.89	0.89	0.51	0.61	0.98	0.96	1.0	0.94	-0.18	0.61	0.48	0.15	0.7	0.97	0.92	0.12	0.98	0.99
Total Current Liabilities	0.86	0.98	0.99		0.57	-0.77	-0.96	0.98	0.92	0.92	0.58	0.68	0.97	0.96	0.99	0.96	-0.18	0.68	0.53	0.23	0.77	0.97	0.93	0.11	0.98	0.99
Total Stockholder Equity	0.71	0.5	0.62	0.57		-0.2	-0.34	0.45	0.36	0.36	-0.21	-0.12	0.69	0.41	0.56	0.44	0.12	-0.08	-0.1	-0.24	-0.05	0.67	0.64	0.66	0.5	0.56
Net Debt	-0.8	-0.77	-0.72	-0.77	-0.2		0.78	-0.8	-0.95	-0.95	-0.75	-0.76	-0.69	-0.73	-0.76	-0.91	0.23	-0.78	-0.67	-0.79	-0.89	-0.66	-0.62	-0.13	-0.77	-0.75
Retained Earnings	-0.74	-0.97	-0.94	-0.96	-0.34	0.78		-0.98	-0.92	-0.92	-0.73	-0.82	-0.9	-0.98	-0.96	-0.94	0.28	-0.8	-0.62	-0.29	-0.88	-0.91	-0.88	0.12	-0.97	-0.95
Accounts Payable	0.81	0.95	0.95	0.98	0.45	-0.8	-0.98		0.92	0.92	0.69	0.78	0.93	0.97	0.96	0.94	-0.3	0.77	0.6	0.32	0.85	0.96	0.94	0.02	0.96	0.94
Cash	0.87	0.93	0.89	0.92	0.36	-0.95	-0.92	0.92		1.0	0.7	0.76	0.86	0.9	0.93	0.99	-0.23	0.77	0.64	0.56	0.89	0.83	0.78	0.09	0.93	0.92
Cash And Short Term Investments	0.87	0.93	0.89	0.92	0.36	-0.95	-0.92	0.92	1.0		0.7	0.76	0.86	0.9	0.93	0.99	-0.23	0.77	0.64	0.56	0.89	0.83	0.78	0.09	0.93	0.92
Common Stock Total Equity	0.42	0.59	0.51	0.58	-0.21	-0.75	-0.73	0.69	0.7	0.7		0.96	0.5	0.62	0.56	0.65	-0.36	0.99	0.86	0.61	0.9	0.49	0.5	-0.27	0.58	0.53
Common Stock Shares Outstanding	0.48	0.68	0.61	0.68	-0.12	-0.76	-0.82	0.78	0.76	0.76	0.96		0.58	0.74	0.66	0.72	-0.28	0.97	0.74	0.54	0.93	0.61	0.61	-0.26	0.68	0.64
Other Current Assets	0.87	0.94	0.98	0.97	0.69	-0.69	-0.9	0.93	0.86	0.86	0.5	0.58		0.9	0.96	0.9	-0.2	0.6	0.54	0.13	0.65	0.96	0.92	0.22	0.94	0.96
Other Stockholder Equity	0.75	0.98	0.96	0.96	0.41	-0.73	-0.98	0.97	0.9	0.9	0.62	0.74	0.9		0.97	0.92	-0.28	0.71	0.53	0.2	0.82	0.92	0.88	-0.08	0.98	0.97
Total Liab	0.85	1.0	1.0	0.99	0.56	-0.76	-0.96	0.96	0.93	0.93	0.56	0.66	0.96	0.97		0.96	-0.19	0.66	0.52	0.21	0.76	0.95	0.9	0.08	1.0	1.0
Total Current Assets	0.89	0.96	0.94	0.96	0.44	-0.91	-0.94	0.94	0.99	0.99	0.65	0.72	0.9	0.92	0.96		-0.21	0.73	0.61	0.47	0.85	0.87	0.81	0.11	0.96	0.96
Short Term Debt	-0.06	-0.22	-0.18	-0.18	0.12	0.23	0.28	-0.3	-0.23	-0.23	-0.36	-0.28	-0.2	-0.28	-0.19	-0.21		-0.36	-0.46	-0.21	-0.37	-0.22	-0.25	0.25	-0.23	-0.19
Common Stock	0.51	0.67	0.61	0.68	-0.08	-0.78	-0.8	0.77	0.77	0.77	0.99	0.97	0.6	0.71	0.66	0.73	-0.36		0.85	0.57	0.92	0.6	0.61	-0.21	0.67	0.63
Other Liab	0.43	0.54	0.48	0.53	-0.1	-0.67	-0.62	0.6	0.64	0.64	0.86	0.74	0.54	0.53	0.52	0.61	-0.46	0.85		0.53	0.76	0.44	0.43	-0.14	0.53	0.5
Net Tangible Assets	0.41	0.23	0.15	0.23	-0.24	-0.79	-0.29	0.32	0.56	0.56	0.61	0.54	0.13	0.2	0.21	0.47	-0.21	0.57	0.53		0.65	0.12	0.12	0.11	0.23	0.2
Current Deferred Revenue	0.59	0.78	0.7	0.77	-0.05	-0.89	-0.88	0.85	0.89	0.89	0.9	0.93	0.65	0.82	0.76	0.85	-0.37	0.92	0.76	0.65		0.67	0.65	-0.25	0.78	0.74
Non Current Assets Total	0.84	0.92	0.97	0.97	0.67	-0.66	-0.91	0.96	0.83	0.83	0.49	0.61	0.96	0.92	0.95	0.87	-0.22	0.6	0.44	0.12	0.67		0.99	0.18	0.93	0.93
Non Currrent Assets Other	0.79	0.86	0.92	0.93	0.64	-0.62	-0.88	0.94	0.78	0.78	0.5	0.61	0.92	0.88	0.9	0.81	-0.25	0.61	0.43	0.12	0.65	0.99		0.17	0.87	0.87
Other Assets	0.55	0.02	0.12	0.11	0.66	-0.13	0.12	0.02	0.09	0.09	-0.27	-0.26	0.22	-0.08	0.08	0.11	0.25	-0.21	-0.14	0.11	-0.25	0.18	0.17		0.01	0.06
Long Term Debt	0.82	1.0	0.98	0.98	0.5	-0.77	-0.97	0.96	0.93	0.93	0.58	0.68	0.94	0.98	1.0	0.96	-0.23	0.67	0.53	0.23	0.78	0.93	0.87	0.01		1.0
Non Current Liabilities Total	0.84	1.0	0.99	0.99	0.56	-0.75	-0.95	0.94	0.92	0.92	0.53	0.64	0.96	0.97	1.0	0.96	-0.19	0.63	0.5	0.2	0.74	0.93	0.87	0.06	1.0

Click cells to compare fundamentals

Axsome Therapeutics Account Relationship Matchups

Axsome Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	220.5M	186.1M	(338.4M)	331.5M	588.2M	617.6M
Short Long Term Debt Total	19.9M	50.1M	49.7M	94.7M	186.4M	195.7M
Other Current Liab	683.2K	8.7M	9.3M	57.5M	95.6M	100.4M
Total Current Liabilities	24.5M	23.4M	23.1M	96.6M	138.9M	145.8M
Total Stockholder Equity	(175.9M)	(278.8M)	(409.2M)	109.6M	191.0M	200.5M
Net Debt	(200.0M)	(133.8M)	(36.8M)	(106.2M)	(199.8M)	(189.8M)
Retained Earnings	(175.9M)	(278.8M)	(409.2M)	(596.3M)	(835.6M)	(793.8M)
Accounts Payable	10.9M	13.5M	13.1M	38.6M	40.7M	42.7M
Cash	220.0M	183.9M	86.5M	200.8M	386.2M	405.5M
Cash And Short Term Investments	220.0M	183.9M	86.5M	200.8M	386.2M	405.5M
Common Stock Total Equity	3.0K	3.7K	3.7K	3.8K	4.3K	2.7K
Common Stock Shares Outstanding	34.0M	37.2M	37.6M	40.7M	45.4M	30.1M
Liabilities And Stockholders Equity	(134.1M)	(206.5M)	(338.4M)	331.5M	588.2M	617.6M
Other Current Assets	413.1K	148.4K	45.3K	5.6M	8.1M	8.5M
Other Stockholder Equity	(3.7K)	392.6M	424.8M	705.9M	1.0B	1.1B
Total Liab	41.8M	72.3M	70.8M	221.9M	397.3M	417.1M
Total Current Assets	220.4M	184.0M	86.5M	245.6M	504.3M	529.5M
Short Term Debt	2.6M	1.2M	620.7K	425K	2.5M	1.4M
Common Stock	3.7K	3.7K	3.8K	4.4K	5K	3.2K
Net Tangible Assets	178.7M	113.8M	15.6M	39.6M	45.5M	52.6M
Non Current Assets Total	170.5K	2.1M	1.3M	85.8M	84.0M	88.2M
Non Currrent Assets Other	139.9K	317.4K	322.9K	14.7M	11.0M	11.6M
Other Assets	139.9K	2.1M	(426.1M)	14.7M	13.2M	13.9M
Long Term Debt	17.3M	48.3M	49.1M	94.3M	178.1M	187.0M
Non Current Liabilities Total	17.3M	48.9M	49.1M	125.4M	258.4M	271.3M
Property Plant And Equipment Net	30.6K	1.8M	944.0K	1.1M	7.6M	8.0M
Property Plant And Equipment Gross	30.6K	1.8M	944.0K	1.1M	7.6M	8.0M
Property Plant Equipment	30.6K	52.6K	283.8K	1.1M	1.3M	1.4M
Retained Earnings Total Equity	(107.6M)	(175.9M)	(278.8M)	(409.2M)	(368.3M)	(349.9M)
Long Term Debt Total	3.6M	17.3M	48.3M	49.1M	56.5M	59.3M
Capital Surpluse	108.5M	354.6M	392.6M	424.8M	488.5M	264.6M
Net Invested Capital	198.7M	162.1M	64.7M	203.8M	369.0M	387.5M
Net Working Capital	195.9M	160.6M	63.5M	149.1M	365.4M	383.7M
Capital Stock	3.7K	3.7K	3.8K	4.4K	5K	4.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:

How To Invest In Axsome

Details

Is Axsome Stock a good investment?

Details

What is Axsome Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.58)

Revenue Per Share

7.108

Quarterly Revenue Growth

0.813

Return On Assets

(0.26)

Return On Equity

(1.72)

The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Axsome Capital Expenditures vs Net Income Analysis

Capital Expenditures vs Net Income

Capital Expenditures vs Net Income Correlation Analysis

Correlation Coefficient

Capital Expenditures

Net Income

Axsome Therapeutics fundamental ratios Correlations

Axsome Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Axsome Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Short Long Term Debt Total
Long Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt	+ 1.0	Total Liab

Other Stockholder Equity	- 0.98	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Long Term Debt	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Short Long Term Debt Total
Total Liab	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities